The Discounted Cash Flow (DCF) valuation of Nabriva Therapeutics PLC (NBRV) is (2,093.10) USD. With the latest stock price at 1.42 USD, the upside of Nabriva Therapeutics PLC based on DCF is -147501.7%.
Based on the latest price of 1.42 USD and our DCF valuation, Nabriva Therapeutics PLC (NBRV) is a sell. selling NBRV stocks now will result in a potential gain of 147501.7%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 6.3% - 8.4% | 7.4% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | (5,209.54) - (1,339.08) | (2,093.10) |
| Upside | -366968.7% - -94401.3% | -147501.7% |